Advances and challenges in hereditary cancer pharmacogenetics.

about

Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.

P2860

Q38844500-1B68389C-502C-47F7-9D0F-EC33829EE75F Q47786696-2F1F8F40-94B9-4015-8CE0-F983AE25BFDA

P2860

Advances and challenges in hereditary cancer pharmacogenetics.

Item

http://www.wikidata.org/entity/Q38948499

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Advances and challenges in hereditary cancer pharmacogenetics.

@en

type

Item

label

Advances and challenges in hereditary cancer pharmacogenetics.

@en

prefLabel

Advances and challenges in hereditary cancer pharmacogenetics.

@en

P1476

Advances and challenges in hereditary cancer pharmacogenetics.

@en

P2093

Anneke Nina Werk

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

P304

73-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1233965

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ingolf Cascorbi

P577

2016-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27603572

http://www.w3.org/2001/XMLSchema#string

Advances and challenges in hereditary cancer pharmacogenetics.

about

P2860

P2860

Advances and challenges in hereditary cancer pharmacogenetics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698